Summary
Gilead Sciences, Inc. (GILD) filed an amendment to its Current Report on Form 8-K to provide previously omitted financial information related to its acquisition of Immunomedics, Inc. The filing includes historical financial statements of Immunomedics as of December 31, 2019, and June 30, 2020, along with pro forma combined financial information reflecting the impact of the acquisition. This supplemental information is crucial for investors to assess the financial implications and potential performance of the combined entity following the Immunomedics acquisition, which was completed in October 2020. The provided financial statements offer a deeper look into Immunomedics' financial standing prior to the acquisition, including its balance sheets, statements of comprehensive loss, changes in stockholders' equity, and cash flows. The pro forma information, while not indicative of future results, provides a hypothetical view of the combined company's financial position as of June 30, 2020, and its operations for the year ended December 31, 2019, and the six months ended June 30, 2020. Investors should review these exhibits to gain a more comprehensive understanding of the transaction's financial footprint.
Key Highlights
- 1Gilead Sciences (GILD) filed an 8-K/A amendment to provide financial details for the acquisition of Immunomedics, Inc.
- 2The amendment includes historical audited financial statements of Immunomedics for periods ending December 31, 2019 and 2018.
- 3Unaudited condensed consolidated financial statements for Immunomedics as of and for the six months ended June 30, 2020 and 2019 are also provided.
- 4The filing contains unaudited pro forma condensed combined financial information for Gilead, giving effect to the Immunomedics acquisition.
- 5Pro forma balance sheet as of June 30, 2020, and statements of operations for the year ended December 31, 2019, and six months ended June 30, 2020, are included.
- 6This filing supplements the initial 8-K report filed on October 23, 2020, which announced the completion of the Immunomedics acquisition.
- 7The acquisition of Immunomedics was completed in October 2020.